Celecoxib Augmentation of Continuously Ill Patients with Schizophrenia

Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophr...

Full description

Saved in:
Bibliographic Details
Published in:Biological psychiatry (1969) 2005-06, Vol.57 (12), p.1594-1596
Main Authors: Rapaport, Mark Hyman, Delrahim, Katia K., Bresee, Catherine J., Maddux, Rachel E., Ahmadpour, Oliver, Dolnak, Douglas
Format: Article
Language:English
Subjects:
Adult
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Antipsychotic Agents - therapeutic use
Augmentation strategies
Celecoxib
cyclooxygenase-2 inhibitor
Double-Blind Method
Drug Synergism
Female
Humans
Male
Middle Aged
Neuropsychological Tests
Placebos
Psychiatric Status Rating Scales
psychoimmunology
psychopathology
Pyrazoles - therapeutic use
schizophrenia
Schizophrenia - drug therapy
Sulfonamides - therapeutic use
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous reports have demonstrated a beneficial effect of celecoxib adjunctive therapy for patients with an acute exacerbation of schizophrenia. We investigated the effects of celecoxib augmentation of atypical antipsychotic medications for continuously symptomatic outpatient subjects with schizophrenia to further extend these findings. We hypothesized that celecoxib augmentation therapy would improve psychopathology ratings compared with placebo. Thirty-eight symptomatic outpatient subjects meeting DSM-IV criteria for schizophrenia and on a stable dose of an atypical antipsychotic medication for at least three months were randomized to receive 8 weeks of double blind placebo or celecoxib (400 mg/day) augmentation. Measures of psychopathology, functional disability, and extrapyramidal side effects were performed throughout the study. The treatment cohorts did not differ on any of the clinical outcome measures. Celecoxib augmentation of continuously ill outpatient subjects with schizophrenia did not improve clinical symptoms or measures of disability.
ISSN:0006-3223
1873-2402
DOI:10.1016/j.biopsych.2005.02.024